Analyte detection by selective labeling of biological samples

The method of selective labeling and mild dehybridization in biological samples allows for multiple cycles of target analyte analysis, enhancing the number of biomarkers that can be identified and quantified while preserving sample integrity.

JP2024163169AActive Publication Date: 2024-11-21AKOYA BIOSCIENCES INC
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024149932
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-04
Filing Date
2024-08-30
Publication Date
2024-11-21
Estimated Expiration
2040-02-04

AI Technical Summary

Technical Problem

Existing immunohistochemical methods for target analyte labeling in biological samples are limited by the number of biomarkers that can be simultaneously analyzed due to dye interference and the aggressive conditions required for antibody removal, which can damage the sample and affect integrity.

Method used

A method involving sequential labeling and mild dehybridization of oligonucleotides to selectively deposit labeled species near target analytes, allowing multiple cycles of analysis without damaging the sample.

Benefits of technology

Enables the identification and quantification of multiple target analytes with high specificity and integrity, overcoming the limitations of conventional methods by maintaining sample integrity and reducing dye interference.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163169000003
    Figure 2024163169000003
  • Figure 2024163169000004
    Figure 2024163169000004
  • Figure 2024163169000005
    Figure 2024163169000005
Patent Text Reader

Abstract

To detect biological analytes in a sample by selective labeling of the sample.SOLUTION: A method includes: contacting a biological sample having a first target analyte with a first agent, where the first agent includes a first binding species that specifically binds to the first target analyte, and a first oligonucleotide conjugated to the binding species; contacting the biological sample with a second agent, where the second agent includes a first reactive species and a second oligonucleotide conjugated to the first reactive species, so as to hybridize at least a portion of the second oligonucleotide to at least a portion of the first oligonucleotide; and contacting the biological sample with a first labeling species, where the first labeling species reacts with the first reactive species to deposit the first labeling species or a derivative thereof in the biological sample.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 801,011, filed February 4, 2019, and U.S. Provisional Patent Application No. 62 / 801,009, filed February 4, 2019, the entire contents of each of which are incorporated herein by reference.

[0002] This disclosure relates to the detection of biological analytes in a sample by selective labeling of the sample. [Background technology]

[0003] Antibodies are used to selectively bind to a wide variety of proteins in biological samples. Immunohistochemistry methods typically involve binding a dye-conjugated antibody to a complementary marker, thereby labeling the marker with a dye. Detection of the fluorescent emission from the dye label reveals the presence of the marker in the sample. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Patent No. 10,126,242 [Patent Document 2] U.S. Patent No. 7,555,155 [Patent Document 3] PCT Patent Publication Number WO2005 / 040769 [Non-patent literature]

[0005] [Non-Patent Document 1] Faget et al., Methods Mol. Biol. 1318: 161-72 (2015) [Non-Patent Document 2] L. Jimenez and D. Landgrebe, "Hyperspectral Data Analysis and Feature Reduction Via Projection Pursuit," IEEE Transactions on Geoscience and Remote Sensing, Vol. 37, No. 6, pp. 2653-2667, November 1999. Summary of the Invention [Means for solving the problem]

[0006] This disclosure features methods for selectively applying dyes and other labeling species to a sample to identify and quantify specific target analytes in the sample. After identification and / or quantification, additional dyes and labeling substances can be added to the sample to identify and quantify additional specific target analytes. In such a manner, a series of successive labeling and detection cycles can be performed to selectively identify and quantify specific target analytes in the sample.

[0007] The method can be carried out by binding a plurality of first substances to the sample, each of which comprises a binding species that specifically binds to a different target analyte in the sample and a different first oligonucleotide conjugated to the binding species. A second substance is then introduced, which comprises a second oligonucleotide conjugated to a reactive species. The second oligonucleotide hybridizes to the first oligonucleotide of one of the first substances, localizing the second substance to a location in the sample that corresponds to the target analyte associated with the first substance. The reaction between the reactive species and the introduced labeling substance deposits the labeling substance in close proximity to the target analyte. The second substance can then be removed by dehybridization under relatively mild conditions, ensuring that each of the first substances remains bound to the sample. Additional labeling cycles can then be carried out in which different second substances are introduced, each of which comprises a different second oligonucleotide conjugated to a reactive species. By selecting a second material having a second oligonucleotide that is complementary to a particular first oligonucleotide, a particular target analyte can be selectively labeled with a different labeling material. The relatively mild conditions under which the second material is removed from the sample ensure that the first material remains bound to the sample and sample integrity is maintained.

[0008] In one aspect, the disclosure features a method that includes the steps of: (i) contacting a biological sample that includes a first target analyte with a first substance, the first substance including a first binding species that specifically binds to the first target analyte and a first oligonucleotide conjugated to the binding species; (ii) contacting the biological sample with a second substance including a first reactive species and a second oligonucleotide conjugated to the first reactive species to hybridize at least a portion of the second oligonucleotide to at least a portion of the first oligonucleotide; (iii) contacting the biological sample with a first labeling species, the first labeling species reacting with the first reactive species to deposit the first labeling species or a derivative thereof in the biological sample; (iv) contacting a first oligonucleotide with a first reactive species to hybridize at least a portion of the first oligonucleotide with the ... removing the second material from the biological sample after deposition of the labeled species or a derivative thereof; (v) contacting the biological sample with a third material, the third material comprising a second binding species that specifically binds to a second target analyte in the biological sample and a third oligonucleotide conjugated to the second binding species; (vi) contacting the biological sample with a fourth material, the fourth material comprising a second reactive species and a fourth oligonucleotide conjugated to the second reactive species, to hybridize at least a portion of the fourth oligonucleotide to at least a portion of the third oligonucleotide; (vii) contacting the biological sample with a second labeled species, the second labeled species reacting with the second reactive species to deposit the second labeled species or a derivative thereof in the biological sample.

[0009] Embodiments of the method may include any one or more of the following features.

[0010] The first reactive species may comprise a catalytic substance, e.g., an enzyme such as horseradish peroxidase. The first labeled species may comprise a dye. The first labeled species may comprise a conjugate of an inactive tyramide or a derivative thereof and a dye.

[0011] The step of contacting the biological sample with the first labeled species includes converting the first labeled species into a conjugate of an active tyramide or a derivative thereof and a dye, wherein the active tyramide or a derivative thereof binds to the biological sample in close proximity to the second substance.

[0012] The first binding species may comprise an antibody or an antibody fragment.

[0013] The first oligonucleotide and / or the second oligonucleotide may comprise at least 10 nucleotides. The nucleotide sequences of the first and second oligonucleotides may be at least 70% complementary. The second oligonucleotide may comprise a greater number of nucleotides than the first oligonucleotide.

[0014] The second oligonucleotide may contain multiple contiguous, non-contiguous nucleotide sequences that are complementary to different portions of the sequence of the first oligonucleotide.

[0015] The first and second reactive species can be the same. The first and second reactive species can each comprise an enzyme, for example, horseradish peroxidase.

[0016] The first and third oligonucleotides can be different. The second and fourth oligonucleotides can be different.

[0017] The first labeled species may include a first dye and the second labeled species may include a second dye that is different from the first dye.

[0018] The first binding species may comprise a first antibody or a first antibody fragment and the second binding species may comprise a second antibody or a second antibody fragment, the first and second binding species being capable of selectively binding to different first and second target analytes in a biological sample.

[0019] The first oligonucleotide may comprise a nucleotide sequence of RNA bases and / or a nucleotide sequence of DNA bases. The first oligonucleotide may comprise at least one synthetic nucleotide. The first oligonucleotide may be completely single-stranded or, alternatively, partially double-stranded.

[0020] Dyes may include chromogenic or fluorescent species.

[0021] Embodiments of the method may also include any of the other features described herein, including any combination of features, even if described in the context of different embodiments, unless expressly stated otherwise.

[0022] In another aspect, the disclosure features a reagent kit that includes a first substance including a first binding species that specifically binds to a first target analyte of a biological sample and a first oligonucleotide conjugated to the first binding species; a second substance including a second binding species that specifically binds to a second target analyte of the biological sample and a second oligonucleotide conjugated to the second binding species; a third substance including a reactive species and a third oligonucleotide conjugated to the reactive species; a fourth substance including a reactive species and a fourth oligonucleotide conjugated to the reactive species; a first labeled species; and a second labeled species, wherein each of the first and second labeled species reacts with the reactive species to deposit the first and second labeled species or derivatives thereof, respectively, in the biological sample.

[0023] An embodiment of the reagent kit may include any of the features described herein, including any combination of features, even if described in conjunction with a different embodiment, unless expressly stated otherwise.

[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the subject matter herein, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Additionally, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0025] The details of one or more embodiments are set forth in the accompanying drawings and the description below. Other features and advantages will be apparent from the description, drawings, and claims. [Brief description of the drawings]

[0026] [Figure 1] FIG. 1 is a schematic diagram showing an example sequence of steps for the analysis of a biological sample. [Figure 2A] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 2B] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 2C] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 2D] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 3A] 1 is a flow chart illustrating an example series of steps for the analysis of a biological sample. [Figure 3B] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 3C] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 3D] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 3E] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 4A]FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 4B] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 4C] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 4D] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 4E] FIG. 1 is a schematic diagram showing the steps of a method for sample analysis. [Figure 5A] FIG. 1 is a schematic diagram showing examples of oligonucleotides. [Figure 5B] FIG. 1 is a schematic diagram showing examples of oligonucleotides. [Figure 5C] FIG. 1 is a schematic diagram showing examples of oligonucleotides. [Figure 5D] FIG. 1 is a schematic diagram showing examples of oligonucleotides. [Figure 5E] FIG. 2 is a schematic diagram showing an example of a first substance. [Figure 5F] FIG. 2 is a schematic diagram showing an example of a second substance. [Figure 6] FIG. 1 is a schematic diagram illustrating an example of a multispectral imaging system. [Figure 7] FIG. 2 is a schematic diagram illustrating an example of a control device. [Figure 8A] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 8B] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 8C] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 8D] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 9A] 13 shows images of tissue sections labeled with different reporting substances and labeling moieties. [Figure 9B] 13 shows images of tissue sections labeled with different reporting substances and labeling moieties. [Figure 9C] 13 shows images of tissue sections labeled with different reporting substances and labeling moieties. [Figure 10A]13 is an image of tissue sections labeled with different labeling moieties. [Figure 10B] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 10C] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 10D] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 10E] 13 is an image of tissue sections labeled with different labeling moieties. [Figure 10F] 13 is an image of tissue sections labeled with different labeling moieties. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] Like reference symbols in the various drawings indicate like elements.

[0028] Introduction The analysis of multiple target analytes in biological samples is an important aspect of modern research methodology. For example, by identifying and quantifying multiple disease markers, complex regulatory and co-expression relationships in cells can be elucidated, which allows validation of models of disease progression and aids in the development of targeted therapeutics that can interfere with key aspects of that progression.

[0029] A variety of different techniques are used to identify and quantify multiple target analytes in a biological sample. For example, a technique for targeting multiple expressed biomarkers (e.g., antigens, peptides) includes exposing the sample to a set of probes, each of which contains an antibody that specifically binds to one of the biomarkers and is conjugated to a different dye species. To target N different biomarkers in a sample, N different types of probes are introduced, each of which stains one type of biomarker with one of the N different dyes. The emission (e.g., fluorescence) from each of the different probe dyes is then measured to identify and quantify the N different biomarkers in the sample.

[0030] In such methods, the emission from each of the different probe dyes is differentiated to separately identify and quantify each of the different biomarkers targeted by the probe. In practical terms, this may impose useful limits on the extent to which multiple biomarkers can be analyzed, as it may become increasingly difficult to separate and quantify the emission measurements corresponding to the different probe dyes as the number of such dyes in a sample increases. For example, even with strategic selection of probe dyes and relatively sophisticated methods for decomposing fluorescent emission measurements into contributions from individual component dye emission spectra, such methods may be limited to simultaneous multiplexed interrogation of about 10 different biomarkers in a sample.

[0031] The aforementioned immunohistochemical methods for target analyte labeling may also be limited by the amount of probe dye that can be delivered to specifically label each of the target analytes in a sample. Since the probe dye is conjugated to a specific antibody, the amount of probe dye that can be applied to a specific location in a sample directly depends on the number of probe dye moieties that are directly attached to the antibody that binds to the analyte at that location. Therefore, certain immunohistochemical methods are somewhat limited in their ability to amplify the signal generated from a specific target analyte by selectively depositing a larger amount of probe dye at the location corresponding to those target analytes.

[0032] To further expand the number of target analytes in a sample that can be identified and quantified, conventional histochemical labeling methods can be modified to include an antibody removal step. For example, in a first round of sample analysis, a set of N different dye-conjugated antibodies can be used to label the sample, and N different biomarkers corresponding to the N different probes can be identified and quantified in the sample by measuring the emission from the N different dyes. An antibody removal step can then be performed in which the N different probes are removed from the sample. Subsequently, a new set of M different dye-conjugated antibodies is used to label the sample, with the M antibodies labeling different target analytes than the previous N probes. Measuring the emission from the M different dyes of this second set of probes results in the identification and quantification of the second set of M different biomarkers in the sample. This methodology can be expanded with multiple cycles of antibody removal and multiplexed labeling.

[0033] However, the preparation conditions used to remove bound probe antibodies from a sample can be relatively time-consuming and aggressive, and can adversely affect the integrity of a certain type of sample. Thus, the number of such labeling and antibody removal cycles that can be performed before the sample is damaged may be limited. Furthermore, depending on the nature of the binding between a particular antibody and the corresponding biomarker in the sample, it may be difficult to completely remove each of the probes from the sample after each analysis cycle. If a probe is not completely removed from the sample, a certain amount of its corresponding dye label will remain in the sample. The emission from the remaining dye label in the next analysis cycle may interfere with the emission from the dyes conjugated to other probes, resulting in inaccurate quantification of a certain biomarker in the sample. Thus, the number of multiplexed labeling and detection that can be effectively performed may be limited by the extent to which the dye-conjugated antibody-based probes can be removed from the sample.

[0034] In certain common analytical procedures, dye quenching methods are used to eliminate the signal generated from the dye conjugated to the remaining antibody in the sample. However, these methods can also be difficult and time-consuming to carry out. For example, it can be a challenge to apply a dye quenching reagent that completely eliminates the contribution from the dye conjugated to the remaining antibody, and yet does not interfere with the signal generated by the dye conjugated to the next antibody applied, and also does not excessively affect the biochemical, structural, and spectral properties of the sample.

[0035] This disclosure features a method for performing multiplexed labeling, identification, signal amplification, and quantification of target analytes in a biological sample. The method can be used to perform multiple cycles of target analyte labeling, detection, and removal of certain agents involved in the labeling process without disrupting antibody-biomarker binding in the sample. Instead, removal of agents involved in the labeling process is performed by dehybridizing the agents under relatively mild conditions, preserving sample integrity and ensuring that agent removal during each labeling and detection cycle is near complete. As a result, little or no species label crossover occurs. Instead, each target analyte in a sample can be selectively labeled with a different labeling species, and deposition of each labeling species is highly confined to an area of ​​the sample that specifically corresponds to the location of a particular target analyte.

[0036] Analysis of target analytes This disclosure describes a variety of different analytical methodologies for identifying and quantifying multiple target analytes in a biological sample. Figure 1 is a flow chart 100 showing an example sequence of steps for carrying out one method of sample analysis. In a first step 102, a biological sample containing a target analyte is contacted with a first substance that specifically binds to the target analyte. This first step is illustrated diagrammatically in Figure 2A. In Figure 2A, a biological sample 202 contains a target analyte 210. The sample 202 is contacted with a first substance 204. The first substance 204 includes a binding species 206 that specifically binds to the target analyte 210, and a first oligonucleotide 208 that is conjugated to the binding species 206. In this way, the first substance 204 is specifically localized to a location in the sample that corresponds to the target analyte 210.

[0037] As used herein, the terms "contact" and "contacting" refer to the association of a substance, species, moiety, or other element with a sample or with another substance, species, moiety, or element such that the two interact with one another. For example, when a sample 202 is "contacted" with a first and second substance, labeling species, and reporting substance, these substances and species associate with the sample in such proximity that they interact with the sample and can bind to the sample or to other substances, species, moieties, and elements that have already contacted, bound to, hybridized with, and / or deposited within the sample.

[0038] Returning to FIG. 1, in the next step 104, the sample is contacted with a second substance that associates with the first substance. This step is illustrated diagrammatically in FIG. 2B. In FIG. 2B, the second substance 216 is contacted with the sample 202. The second substance 216 comprises a second oligonucleotide 212 conjugated to a reactive species 214. The second oligonucleotide 212 is at least partially complementary to the first oligonucleotide 208, such that the first and second oligonucleotides hybridize. In this way, the second substance 216 is localized in the sample at the same location as the first substance 204, and therefore at a location corresponding to the target analyte 210.

[0039] Returning again to FIG. 1, in step 106 the sample is contacted with a labeled species. The labeled species reacts with the reactive species of the second material from step 104, depositing the labeled species in the sample at a location proximate to the second material. This step is illustrated diagrammatically in FIG. 2C, in which a labeled species 218 is contacted with the sample. As shown in FIG. 2C, the labeled species 218 reacts with the reactive species 214 in a reaction represented by arrow 220. The reaction deposits the labeled species 218, or a derivative thereof, in the sample at a location 222 proximate to the second material 216, and thus proximate to the target analyte 210. In this manner, the deposited labeled species 218 (or a derivative thereof) is spatially co-localized with the target analyte 210.

[0040] 1, after deposition of the labeled species or derivatives thereof in step 106, the labeled species is detected in step 108 to identify and / or quantify the target analyte 210 in the sample 202. After detection of the labeled species or derivatives thereof, the procedure illustrated in Flowchart 100 ends.

[0041] The foregoing procedures and other methods described herein can be used to identify and quantify a wide variety of different analytes 210 in a biological sample 202. Examples of analytes 210 include, but are not limited to, antigens, peptides, proteins, and other amino acid-containing moieties. Additional examples of analytes 210 include, but are not limited to, oligonucleotides, nucleic acid fragments, including oligonucleotides containing DNA bases, RNA bases, both DNA and RNA bases, and synthetic bases, and lipids.

[0042] The methods described herein are suitable for the identification and quantification of many different clinically relevant biomarkers in biological samples, particularly those expressed in tumor tissue, tumor microenvironment, and tissue representative of other disease states. Examples of such biomarkers corresponding to analyte 210 include, but are not limited to, tumor markers such as Sox10, S100, pan-cytokeratin, PAX5, PAX8, immune cell identifiers such as CD3, CD4, CD8, CD20, FoxP3, CD45RA, CD45LCA, CD68, CD163, CD11c, CD33, HLADR, activation markers such as Ki67, Granzyme B, and checkpoint-related markers such as TIM3, LAG3, PD1, PDL1, CTLA4, CD80, CD86, IDO-1, VISTA, CD47, CD26.

[0043] The methods described herein can be used to analyze a variety of different types of biological samples 202. In some embodiments, the biological sample 202 can be fresh, frozen, or fixed. The biological sample can be of animal origin, such as from a human, mouse, rat, cow, pig, sheep, monkey, rabbit, fruit fly, frog, nematode, or marmot. The biological sample can include formalin-fixed paraffin-embedded (FFPE) tissue section, frozen tissue section, fresh tissue, cells obtained from a subject (e.g., by fine needle aspiration or other technique), cultured cells, biological tissue, biological fluid, homogenate, or unknown biological sample.

[0044] In certain embodiments, the biological sample 202 can be immobilized on a surface. For example, the surface can be a slide, a plate, a well, a tube, a membrane, or a film. In some embodiments, the biological sample 202 can be mounted on a slide. In certain embodiments, the biological sample 202 can be fixed using a fixative, such as an aldehyde, an alcohol, an oxidizing agent, mercury, a picrate, HOPE fixative, or another fixative. The biological sample can alternatively or additionally be fixed using heat fixation. Fixation can also be achieved by immersion or perfusion.

[0045] In some embodiments, the biological sample 202 can be frozen. For example, the biological sample can be frozen below 0° C., below −10° C., below −20° C., below −30° C., below −40° C., below −50° C., below −60° C., below −70° C., or below −80° C.

[0046] In certain embodiments, the biological sample 202 can be fixed in a three-dimensional form. The three-dimensional form can include, for example, a frozen block, a paraffin block, or a frozen liquid. For example, the biological sample 202 can be a block of frozen animal tissue in an optimal cutting temperature compound. The block of tissue can be frozen or fixed. In some embodiments, the block of tissue can be cut to expose a surface that can be the surface contacted by the first substance, as discussed above.

[0047] In some embodiments, where the biological sample 202 corresponds to a block, the block can be sliced ​​to produce serial sections of the block, each of which can be analyzed by the methods described herein. By doing so, three-dimensional information can be obtained about the identity and / or amount of one or more target analytes in the sample (e.g., information as a function of depth within the sample).

[0048] Typically, the binding species 206 is selected to target a particular analyte in the sample 202. The methods described herein can be performed with a wide variety of different types of binding species. For example, to target a particular antigen, peptide, protein, or other amino acid-containing species in the sample 202, the binding species 206 can include an antibody or antibody fragment. The antibody or antibody fragment can include any one of the different types of antibody species, including, but not limited to, immunoglobulin G (IgG), immunoglobulin M (IgM), polyclonal antibodies, monoclonal antibodies, single chain fragment variable (scFv) antibodies, nanobodies, antigen-binding fragments (Fab), and diabodies. The antibodies and antibody fragments can be of mouse, rat, rabbit, human, camel, or goat origin. In some embodiments, the antibody or antibody fragment can be raised against an antigen of a human, mouse, rat, cow, pig, sheep, monkey, rabbit, fruit fly, frog, nematode, or marmot. In certain embodiments, antibodies or antibody fragments may be raised against animal, plant, bacterial, fungal, or protozoan antigens.

[0049] A variety of different binding mechanisms may occur between the binding species 206 and the target analyte 210 in the sample 202. In some embodiments, for example, the binding species 206 (e.g., an antibody or antibody fragment) reversibly binds to the target analyte 210. In certain embodiments, the binding species 206 irreversibly binds to the target analyte 210. The binding between the binding species 206 and the target analyte 210 may occur through the formation of one or more covalent bonds in some embodiments. Alternatively or additionally, the binding species 206 and the target analyte 210 are bound through one or more non-covalent bonds. One or more immobilizing agents may be used to facilitate the formation of covalent and / or non-covalent bonds.

[0050] The specific binding mechanism that occurs between the binding species 206 and the target analyte 210 in the sample 202 depends on the nature of the binding species 206 and the target analyte 210. For example, if the binding species 206 is an antibody or antibody fragment and the target analyte 210 is an antigen, binding occurs between the antigen epitope and the paratope of the antibody or antibody fragment. As another example, if the binding species 206 is an antibody or antibody fragment and the target analyte 210 is a lipid, binding can occur between a recognition site on the antibody or antibody fragment and a lipid head group (e.g., a phospholipid head group).

[0051] Generally, the binding species 206 binds to the target analyte 210 in the sample 202 with a particular sensitivity, where the sensitivity refers to the statistical proportion of target analyte 210 entities in the sample that are correctly recognized and bound by the binding species 206. In some embodiments, the sensitivity of the binding species 206 for the target analyte 210 is 60% or greater (e.g., 70% or greater, 75% or greater, 80% or greater, 85% or greater, 90% or greater, 95% or greater, 99% or greater).

[0052] The binding species 206 also generally bind to the target analyte 210 with a particular specificity, where specificity refers to the statistical proportion or efficiency with which the binding species selectively binds to a particular target analyte 210 over other target analytes in a biological sample. In some embodiments, the binding species 206 has a specificity for the target analyte 210 of at least 60% (e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%).

[0053] The affinity of the binding species 206 for the target analyte 210 generally refers to the strength of binding between the binding species 206 and the target analyte 210, and is expressed as the dissociation constant K d In some embodiments, the affinity of the binding species 206 for the target analyte 210 can be characterized by a value greater than 10 -4 M or less (e.g., 10 -5 M or less, 10 -6 M or less, 10 -7 M or less, 10 -8 M or less, 10-9 M or less, 10 -10 M or less, 10 -11 M or less, 10 -12 M or less, 10 -13 M or less, 10 -14 It is characterized by a dissociation constant of 0.01 M or less.

[0054] In some embodiments, the binding species 206 binds to at least 20% (e.g., at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%) of the target analytes 210 in the sample 202. As discussed above, generally, the binding species 206 selectively binds to the target analytes 210 in the sample 202. As used herein, "selective binding" means that at least 70% or more (e.g., 80% or more, 90% or more, 95% or more) of the binding species 206 in the sample 202 binds to the target analytes 210 rather than other species in the sample 202.

[0055] Oligonucleotides and Hybridization Generally, the first oligonucleotide 208 comprises a plurality of nucleotides. The nucleotides may include, for example, DNA bases (e.g., A, C, G, T), RNA bases (e.g., A, C, G, U), and any combination of DNA and / or RNA bases. The first oligonucleotide 208 may also include non-natural (e.g., synthetic) nucleotides, including DNA and / or RNA analogs. Examples of such synthetic analogs include, but are not limited to, peptide nucleic acids, morpholino and locked nucleic acids, glycol nucleic acids, and threose nucleic acids.

[0056] The sequence of bases in the first oligonucleotide 208 can generally be any sequence. Furthermore, generally, the nucleotides and other moieties in the first oligonucleotide 208 can be conjugated by natural and / or non-natural (e.g., synthetic) linkages.

[0057] In some embodiments, the first oligonucleotide 208 comprises one or more nucleotides capable of base pairing with a complementary nucleotide with a high degree of fidelity. Examples of such nucleotides include, but are not limited to, 7-deaza-adenine, 7-deaza-guanine, adenine, guanine, cytosine, thymine, uracil, 2-deaza-2-thio-guanosine, 2-thio-7-deaza-guanosine, 2-thio-adenine, 2-thio-7-deaza-adenine, isoguanine, 7-deaza-guanine, 5,6-dihydrouridine, 5,6-dihydrothymine, xanthine, 7-deaza-xanthine, hypoxanthine, 7-deaza-xanthine, 2,6 diamino-7-deazapurine, 5-methyl-cytosine, 5-propynyl-uridine, 5-propynyl-cytidine, 2-thio-thymine, and 2-thio-uridine.

[0058] In certain embodiments, the first oligonucleotide 208 may correspond to or contain one or more fragments of a specific nucleic acid species. For example, the first oligonucleotide 208 may correspond to or contain one or more fragments of a locked nucleic acid (LNA), a peptide nucleic acid (PNA), an unlocked nucleic acid (UNA), and / or a morpholino oligomer.

[0059] The length of the first oligonucleotide 208 (e.g., the number of nucleotides in the first oligonucleotide 208) can generally be selected as required to ensure efficient and selective hybridization with the second oligonucleotide 212. In some embodiments, the first oligonucleotide 208 can comprise at least 5 (e.g., at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100) nucleotides.

[0060] In some embodiments, the first oligonucleotide 208 may have between 5-30, between 5-25, between 5-20, between 10-20, between 10-30, between 10-50, between 10-70, between 10-100, between 20-50, between 20-70, between 20-100, between 30-50, between 30-70, between 30-100, between 40-70, between 40-100, between 50-70, between 50-100, between 60-70, between 60-80, between 60-90, or between 60-100 nucleotides.

[0061] In certain embodiments, the first oligonucleotide 208 may have 5 or fewer nucleotides (e.g., 10 or fewer, 15 or fewer, 20 or fewer, 25 or fewer, 30 or fewer, 35 or fewer, 40 or fewer, 45 or fewer, 50 or fewer, 55 or fewer, 60 or fewer, 65 or fewer, 70 or fewer, 75 or fewer, 80 or fewer, 85 or fewer, 90 or fewer, 95 or fewer, or 100 or fewer).

[0062] In some embodiments, the first oligonucleotide 208 can be completely single-stranded. Alternatively, in certain embodiments, the first oligonucleotide 208 can be at least partially double-stranded. The partially double-stranded region of the first oligonucleotide 208 can be at the 3' end of the oligonucleotide, the 5' end of the oligonucleotide, or between the 5' and 3' ends of the oligonucleotide.

[0063] 5A is a schematic diagram of a first oligonucleotide 208 that includes two single-stranded regions 504 and a double-stranded region 502. As discussed above, the double-stranded region 502 can be located at the 3' end of the first oligonucleotide 208, at the 5' end of the first oligonucleotide 208, or at an intermediate position between the 3' and 5' ends. In certain embodiments, the first oligonucleotide 208 can include more than one double-stranded region (e.g., two or more, three or more, four or more, five or more, or even more double-stranded regions).

[0064] The double-stranded region may be formed by a minor oligonucleotide strand 506 that is associated (e.g., hybridized) with a major oligonucleotide strand 508 of a first oligonucleotide 208, as shown in Figure 5A. Alternatively or additionally, the first oligonucleotide 208 may include a secondary structure that allows folding of the single-stranded first oligonucleotide 208. At least partial complementarity between different portions of the single strand allows those portions to hybridize to form one or more double-stranded regions from the single strand.

[0065] One or more double-stranded regions 502 of the first oligonucleotide 208 may each and collectively span a percentage of the total length (e.g., total number of nucleotides) of the first oligonucleotide 208. In some embodiments, for example, one or more of the double-stranded regions individually span, or all of the double-stranded regions collectively span, 1% or more (e.g., 5% or more, 10% or more, 15% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 50% or more) of the total length of the first oligonucleotide 208.

[0066] In general, the second oligonucleotide 212 may include any of the features described above for the first oligonucleotide 208. The second oligonucleotide 212, in some embodiments, may include the same number of nucleotides as the first oligonucleotide 208. Alternatively, in certain embodiments, the second oligonucleotide 212 may include a different number of nucleotides.

[0067] The second oligonucleotide 212 may have the same or a different strand structure as the first oligonucleotide 208. That is, the second oligonucleotide 212 may be single-stranded, double-stranded, or partially double-stranded, regardless of the structure of the first oligonucleotide 208. The second oligonucleotide 212 may include any number of double-stranded regions, as described above for the first oligonucleotide 208, generally spanning a portion of the entire length of the second oligonucleotide 212.

[0068] As discussed above, the second oligonucleotide 212 hybridizes to the first oligonucleotide 208 by base pairing, resulting in the first substance 204 and the second substance 216 co-localizing in the sample at the location of the target analyte 210. The efficiency of hybridization is related, in part, to the degree of complementarity between the sequences of the first and second oligonucleotides. As used herein, the percentage of sequences of two sequences that are complementary refers to the percentage of nucleotides in the shorter of the two sequences that have complementary counterparts at complementary positions in the other sequence such that the two counterparts pair during hybridization. In some embodiments, for example, the sequences of the two oligonucleotides are at least 70% (e.g., at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) complementary.

[0069] As used herein, the term "at least partially complementary" means that two nucleotide sequences are sufficiently complementary that they hybridize. Generally, two nucleotide sequences are at least partially complementary if their sequences are at least 50% complementary.

[0070] Generally, the second oligonucleotide 212 includes at least one binding region that hybridizes with a corresponding binding region of the first oligonucleotide 208. The binding region can be located at the 3' end, the 5' end, or midway between the two ends of the second oligonucleotide. If the second oligonucleotide 212 includes multiple binding regions, any of the binding regions can be located as described above.

[0071] In some embodiments, the binding region of the second oligonucleotide 212 is at least partially complementary to and hybridizes with the 3' end of the first oligonucleotide 208. In certain embodiments, the binding region of the second oligonucleotide 212 is at least partially complementary to and hybridizes with the 5' end of the first oligonucleotide 208. Figure 5B shows a schematic diagram of the first and second oligonucleotides 208 and 212 with respective binding regions 510a and 510b. In Figure 5B, the binding region 510b of the second oligonucleotide is at least partially complementary to the 3' or 5' end of the first oligonucleotide 208.

[0072] In certain embodiments, the binding region 510b of the second oligonucleotide 212 is at least partially complementary to and hybridizes with the intermediate region of the first oligonucleotide 208. Figure 5C shows a schematic diagram in which the binding region 510b of the second oligonucleotide 212 binds to the intermediate binding region 510 of the first oligonucleotide 208.

[0073] In some embodiments, the binding region 510b of the second oligonucleotide 212 is at least partially complementary to and hybridizes with the entire first oligonucleotide 208. In certain embodiments, the binding region 510a of the first oligonucleotide 208 is at least partially complementary to and hybridizes with the entire second oligonucleotide.

[0074] In certain embodiments, one or both of the first and second oligonucleotides 208 and 212 include multiple binding regions separated by one or more non-binding regions. Figure 5D is a schematic diagram showing the first and second oligonucleotides 208 and 212, each of which includes multiple binding regions 510a and 510b, respectively, separated by non-binding regions 512a and 512b, respectively. In general, each of the binding regions can have any of the characteristics discussed above with respect to the first and second oligonucleotides 208 and 212 and their respective binding regions.

[0075] The non-binding regions 512a and 512b can be formed by a variety of different linkage types, including non-complementary nucleotide sequences and spacer portions that do not contain nucleotides. The non-binding regions 512a-b can have the same or different geometric lengths, and the binding regions 510a-b can have the same or different lengths (e.g., the same or different numbers of nucleotides). Within each oligonucleotide (e.g., 208 and / or 212), the binding and non-binding regions can have the same or different lengths.

[0076] In some embodiments, the binding species 206 may be conjugated to a plurality of first oligonucleotides 208 in the first substance. Figure 5E is a schematic diagram showing a first substance 204 in which the binding species 206 is conjugated to three first oligonucleotides 208. Typically, each of the first oligonucleotides 208 has the same nucleotide sequence, such that the second oligonucleotide 212 can hybridize to any of the first oligonucleotides. Although three first oligonucleotides are conjugated to the binding species 206 in Figure 5E, more typically, two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, or even more) first oligonucleotides may be conjugated to the binding species 206. By conjugating more than one first oligonucleotide to the binding species 206, additional reactive species can be selectively deposited in the sample at the location of the target analyte 210, increasing the proportion and amount of labeled species that can be deposited in the sample in the immediate vicinity of that location.

[0077] In some embodiments, the second oligonucleotide 212 of the second substance 216 is conjugated to multiple reactive species 214. FIG. 5F is a schematic diagram showing a second substance 216 in which the second oligonucleotide 212 is conjugated to three reactive species 214. All three reactive species can be the same, or one or more can be different from the others. Although three reactive species 214 are conjugated to the second oligonucleotide 212 in FIG. 5F, more typically, two or more (e.g., three or more, four or more, five or more, six or more, seven or more, eight or more, or even more) reactive species can be conjugated to the second oligonucleotide 212. By conjugating more than one reactive species to the second oligonucleotide 212, the additional reactive species can be selectively deposited in the sample at the location of the target analyte 210, increasing the proportion and amount of labeled species that can be deposited in the sample in the immediate vicinity of that location.

[0078] Reactive and labeled species As discussed above, in the second substance 216, the second oligonucleotide 212 is conjugated to a reactive species 214 that reacts with the labeling species 218. The reactive species 214 may correspond to any one or more of a variety of different chemical or biochemical species and moieties. In some embodiments, for example, the reactive species 214 corresponds to a catalytic substance that catalyzes the reaction of the labeling species 218. Examples of catalytic substances that may correspond to the reactive species 214 include, but are not limited to, enzymes, transition metal-based organometallic moieties, moieties containing peroxidase, and photoactivatable species. Examples of suitable enzymes include, but are not limited to, horseradish peroxidase (HRP) and soybean peroxidase. In some embodiments, the reactive species 214 may include a hemin-containing complex that can mimic HRP, such as hematin.

[0079] Generally, the labeling species 218 includes at least one labeling moiety. A variety of different labeling moieties can be used depending on the nature of the methodology used to identify and quantify the targets 210 in the sample 202. In some embodiments, for example, the labeling species 218 includes a dye. As used herein, a "dye" is a moiety that interacts with incident light, and the light emitted therefrom can be measured and used to detect the presence of the dye in the sample. Generally, the dye can be a fluorescent moiety, an absorptive moiety (e.g., a chromogenic moiety), or another type of moiety that emits light, or the dye, if present, modifies the incident light that passes through or is reflected from the sample, such that the presence of the dye can be determined by measuring the change in the transmitted or reflected light from the sample.

[0080] In certain embodiments, the label moiety may comprise a hapten, which may then (or simultaneously) be conjugated to a dye moiety to provide a label moiety that can be detected by measuring emitted, transmitted, or reflected light from a sample.

[0081] When the labeling moiety of labeling species 218 includes a dye, a wide variety of different dyes can be used. For example, the dye can be a xanthene-based dye, such as a fluorescein dye and / or a rhodamine dye. Examples of suitable fluorescein and rhodamine dyes include, but are not limited to, fluorescein isothiocyanate (FITC), 6-carboxyfluorescein (commonly known by the abbreviations FAM and F), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G5 or G5), 6-carboxyrhodamine-6G (R6G6 or G6), and rhodamine 110.

[0082] The dye may also be a cyanine-based dye. Suitable examples of such dyes include, but are not limited to, the dyes Cy3, Cy5, and Cy7. The dye may also be a coumarin dye (e.g., umbelliferone), a benzimide dye (e.g., any of the Hoechst dyes, such as Hoechst 33258), a phenanthridine dye (e.g., Texas Red), an ethidium dye, an acridine dye, a carbazole dye, a phenoxazine dye, a porphyrin dye, a polymethine dye (e.g., any of the BODIPY dyes), and a quinoline dye.

[0083] Where the dye is a fluorescent moiety, the dye can be a moiety corresponding to any of the following non-limiting examples and / or derivatives thereof: pyrene, coumarin, diethylaminocoumarin, FAM, fluorescein chlorotriazinyl, fluorescein, Rl 10, JOE, R6G, tetramethylrhodamine, TAMRA, Lissamine, naphthofluorescein, Texas Red, Cy3, and Cy5.

[0084] In certain embodiments, the dye may comprise one or more quantum dot-based species. Quantum dot-based fluorophores are available that have fluorescence emission spectra in many different spectral bands, and suitable quantum dot-based dyes can be used as labeling species in the methods described herein.

[0085] Tyramide signal amplification In some embodiments, the reactive species 214 is an enzyme that participates in an enzyme-mediated reaction that can deposit a labeled species 218 (or a derivative thereof) at a location in the sample that is in proximity to the second substance 216 and, therefore, the target analyte 210. As an example of enzyme-mediated deposition of a labeled species, the reactive species 214 can be horseradish peroxidase (HRP), or another species that mimics the activity of HRP. HRP can be used in the methods described herein as a catalytic substance for tyramide signal amplification (TSA).

[0086] To perform TSA, the labeled species 218 includes a labeled moiety (e.g., a dye as described above) conjugated to a tyramide species. When the sample 202 first contacts the labeled species 218, the tyramide species is in an inactive form. However, HRP catalyzes the conversion of the tyramide species to an active form capable of binding to the sample 202. After conversion of the tyramide species to its active form, the labeled moiety binds to the sample 202 at a location proximate to where it was generated (e.g., at the location of the second substance 216 and the target analyte 210). Figure 2C illustrates the deposition of the labeled species 218 (which may include an active tyramide species conjugated to a labeled moiety) at a location 222 proximate to the target analyte 210.

[0087] By adjusting the amount of tyramide-containing labeled species 218 introduced to the sample 202 and the amount of time the enzyme-mediated activation process lasts, the amount of labeled species 218 deposited in the sample 202 can be adjusted. As a result, the signal detected and corresponding to the labeled species 218 (and therefore the target analytes 210) can be "amplified." In the context of this disclosure, amplification refers to the linkage of more than one labeled species 218 to each target analyte 210. For immunohistochemical labeling methods in which each bound antibody is conjugated to a single labeled species (e.g., a single fluorophore moiety), the TSA technique can be used to deposit multiple labeled species 218 (or derivatives thereof) in the sample to generate a measurable signal corresponding to a single target analyte 210, thereby increasing the amplitude or intensity of the measured signal corresponding to a single target analyte relative to a signal otherwise measured from a single labeled species.

[0088] Generally, the ratio of the number of labeled species 218 that can be deposited in the immediate vicinity of a single target analyte 210 in a sample is increased to greater than 1:1 by implementing the TSA methodology described above. In some embodiments, for example, the ratio is 2:1 or greater (e.g., 3:1 or greater, 4:1 or greater, 5:1 or greater, 6:1 or greater, 8:1 or greater, 10:1 or greater, 20:1 or greater, 30:1 or greater, or even higher).

[0089] Amplification offers several important advantages. First, exposure times and measurement times can be reduced because the measurable signal corresponding to the target analyte has a higher amplitude or intensity than would be the case in the absence of amplification. Second, the increased amplitude or intensity of the measurement signal allows for more reliable detection of target analytes that are present in a relatively low concentration in the sample and whose corresponding measurement signals would otherwise be relatively weak in the absence of amplification. Third, the increased amplitude or intensity of the measurement signal makes it easier to compensate for the confounding effects of tissue autofluorescence, as well as detection of the measurement signal against background autofluorescence signals, which would otherwise obscure some or all of the measurement signal.

[0090] Amplification can also be used to adjust the measurement signals corresponding to different target analytes. For example, in a sample in which certain analytes are present in significantly lower concentrations than other analytes, the amplitude or intensity of the measurement signals corresponding to the low concentration analytes can be amplified so that they match more closely the amplitude or intensity of the signals corresponding to the other target analytes in the sample in which they are present in higher concentrations. In this way, the range amplitude or intensity of the measurement signal can be reduced, so that the dynamic range of the measurement system used to detect the measurement signal can also be smaller with respect to the dynamic range that would otherwise be used for the measurement signal in the absence of amplification.

[0091] Furthermore, the presence of low concentration analytes (e.g., very weakly expressed biomarkers) in a sample can be visualized along with higher concentration analytes for co-expression analysis, protein control evaluation, and other comparative analyses that would be more difficult if both the low and higher concentration analytes were not detected and visualized simultaneously.

[0092] When the reactive species 214 corresponds to an enzyme or other catalytic substance, the enzyme or catalytic substance can mediate deposition of the labeled species 218 in the sample by any of a variety of different types of reactions. In some embodiments, the reaction mediated by the enzyme or catalytic substance is an oxidation-reduction reaction, for example (such as TSA for HRP-mediated deposition of tyramide-conjugated labeling moieties). Other examples of suitable enzyme- or catalytic substance-mediated reactions include, but are not limited to, deprotonation, elimination, radical-generating reactions, deprotection, and rearrangement.

[0093] For redox reactions (such as TSA for HRP-mediated deposition of labeled species 218), a variety of different oxidizing and / or reducing agents can be used. In some embodiments, for example, the oxidizing agent is H2O2. A variety of other agents can also be used.

[0094] It should further be noted that while in some embodiments deposition of labeled species 218 (or derivatives thereof) in sample 202 is irreversible, in certain embodiments deposition of labeled species 218 in sample 202 is reversible and labeled species 218 can be removed from sample 202 after deposition by methods such as washing, one or more chemical reactions to liberate labeled species 218, and physical methods such as heating and exposing labeled species 218 to radiation (e.g., photocleavage or photoionization or sputtering).

[0095] The labeled species 218 can be stably associated with the sample 202 for 48 hours or more at room temperature. In some embodiments, samples labeled with labeled species 218 that are refrigerated at 4° C. can be stable for up to at least four weeks, and samples frozen at −20° C. or −80° C. can remain stably associated with labeled species 218 for up to four months or more.

[0096] The stability of the bond between the labeled species 218 and the sample 202 can vary depending on the nature of both the labeled species 218 and the sample 202. Generally, the bond is stable for at least 48 hours when the sample 202 is stored relatively close to or below room temperature. For example, in certain embodiments, the bond is stable for at least 48 hours when the sample 202 is maintained within about 5° C. of room temperature. In certain embodiments, the sample 202 is between 0° C. and 40° C. (e.g., between 10° C. and 40° C., between 15° C. and 40° C., between 20° C. and 40° C., between 25° C. and 40° C., between 30° C. and 40° C., between 35° C. and 40° C., between 0° C. and 35° C., between 5° C. and 35° C., between 10° C. and 35° C., between 15° C. and 35° C., between 20° C. and 35° C., between 25° C. and 35° C., between 30° C. and 35° C., between 0° C. and 30° C., between 5° C. and 30° C., between 10° C. and 30° C., between 15° C. and 30° C. The bond is stable for at least 48 hours when maintained at a temperature of between 0°C, 20°C and 30°C, 25°C and 30°C, 0°C and 25°C, 5°C and 25°C, 10°C and 25°C, 15°C and 25°C, 20°C and 25°C, 0°C and 20°C, 5°C and 20°C, 10°C and 20°C, 15°C and 20°C, 0°C and 15°C, 5°C and 15°C, 10°C and 15°C, 0°C and 10°C, 5°C and 10°C, and 0°C and 5°C.

[0097] Additional methods and embodiments of TSA are described, for example, in Faget et al., Methods Mol. Biol. 1318: 161-72 (2015), the entire contents of which are incorporated herein by reference.

[0098] Multiple analysis 1 and 2C, after labeled species 218 has been detected in the sample, second substance 216 can optionally be removed from the sample. Notably, because first oligonucleotide 208 and second oligonucleotide 212 are hybridized, removal of second substance 216 includes dehybridizing the first and second oligonucleotides. As discussed above, dehybridization can generally be accomplished under significantly milder conditions than the removal of antibodies from a sample that occurs in certain immunohistochemical methods.

[0099] Dehybridization can also be used (i.e., during amplification) to control the amount of labeled species 218 that is deposited in the sample 202. More specifically, dehybridization of the first and second oligonucleotides can be used to terminate a reaction between the reactive species 214 and the labeled species 218 (e.g., a catalytic reaction, such as an enzyme-mediated deposition of the labeled species 218), thereby controlling the amount of time during which deposition of the labeled species 218 in the sample occurs.

[0100] Various methods can be used to achieve dehybridization of the first and second oligonucleotides. In some embodiments, for example, dehybridization of the oligonucleotides can be achieved by exposing the oligonucleotides to one or more chaotropic agents, such as dimethylsulfoxide (DMSO) and formamide, where the molar concentration of the chaotropic agent in the solution is 60% or more (e.g., 70% or more, 80% or more, 90% or more). Alternatively, dehybridization can be performed by washing the sample 202, by heating the sample 202, and by a combination of the aforementioned techniques.

[0101] Dehybridization of the first and second oligonucleotides in the sample 202, followed by a wash step to remove free second substance 216 after dehybridization, results in a sample 202 in which the first substance 204 remains bound to the target analyte 210 through the binding species 206, and the labeling species 218 remains bound to the sample 202 in close proximity to the target analyte 210. In effect, dehybridization returns the sample 202 to a state similar to that shown in Figure 2A, with the addition of the presence of the labeling species 218. Figure 2D shows the sample 202 in schematic form after dehybridization of the first and second oligonucleotides and subsequent removal of free second substance 216 from the sample.

[0102] Some or all of the steps illustrated in Flowchart 100 can optionally be repeated to selectively identify and quantify a second (and subsequent) target analyte 210 in sample 202. Specifically, sample 202 can be contacted with another first substance comprising a binding species 206 that selectively binds to a different target analyte 210 in sample 202 and a first oligonucleotide that is different from the first oligonucleotide of the previous first substance. The sample can then be contacted with another second substance comprising a reactive species (e.g., any of the reactive species described above) and a second oligonucleotide that is at least partially complementary to and hybridizes to the first oligonucleotide of the newly added first substance.

[0103] After addition of additional second material, a new labeled species can be introduced that reacts with the reactive species to deposit the new labeled species (or a derivative thereof) at a location in the sample that is in proximity to the newly added first and second materials, and therefore in proximity to the second target analyte 210 to which the newly added first material selectively binds. The measured signal corresponding to the newly added labeled species can be used to identify and quantify the second target analyte 210 in the sample.

[0104] The newly added second substance can again be removed from the sample by dehybridization of the first and second oligonucleotides, as described above, and additional cycles can be performed to selectively identify and quantify multiple different target analytes 210 in the sample 202.

[0105] Each repetition of some or all of the steps of flowchart 100 is referred to as an analysis cycle, and generally any number of cycles can be performed to selectively identify and quantify different target analytes 210 in the sample 202. In some embodiments, for example, the number of such cycles is N, where N is 2 or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 10 or more, 12 or more, 15 or more, or even more).

[0106] Generally, for each different combination of first and second substances that target different target analytes 210 in the sample for analysis, a different label species 218 is selectively deposited in the sample in close proximity to the particular target analyte 210. By selecting different label species, the different target analytes can be selectively matched by isolating, and optionally quantifying, the contributions to the measured emitted, reflected, or transmitted light from the sample that arise specifically from the different label species. Since each species is effectively "mapped" to the different target analytes, identification and quantification of the specific analytes can be achieved by isolating the measurement signals that correspond to their associated label species.

[0107] Multiple target analytes 210 can also be analyzed by multiplexing the addition of different first and second substances to a sample. Figure 3A is a flow chart 350 showing an example sequence of steps for analyzing N different target analytes in a sample. In general, N can be 2 or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 10 or more, 12 or more, 15 or more, or even more).

[0108] In a first step 352, the sample is contacted with N different first substances, each of which comprises a binding species that specifically binds to one of the N different target analytes and a unique first oligonucleotide conjugated to that binding species. In other words, the binding species and conjugated first oligonucleotide of each of the N first substances are different from the binding species and conjugated first oligonucleotide of the other first substances among the N first substances.

[0109] Next, in step 354, one of the n target analytes is selected for analysis and the sample is contacted with a second substance comprising a reactive species conjugated to a second oligonucleotide that is at least partially complementary to and hybridizes with a first oligonucleotide of the first substance that selectively binds the nth target analyte, such that the second oligonucleotide binds to the sample at a position corresponding to the nth target analyte (and the corresponding nth first substance).

[0110] The sample is then contacted with an nth labeled species that includes a label moiety that is different from the label moieties of the other (n-1) labeled species in step 356. The labeled species reacts with the nth reactive species of the second substance to deposit the nth labeled species in the sample in close proximity to the nth target analyte.

[0111] Next, in step 360, the nth second substance is removed from the sample by dehybridization and washing as previously described. If, in step 362, all N target analytes have been analyzed, the procedure ends in step 366. If not, another nth analyte of the N target analytes is selected for analysis and the procedure returns to step 354.

[0112] The above procedure is illustrated diagrammatically in Figures 3A-3E for a sample containing N=3 target analytes for analysis. Figure 3B is a schematic diagram showing a sample 302 containing three different target analytes 310a-c. In a first step of the analysis of the sample 302, three different first substances are contacted with the sample, each having a different binding species 306a-c that specifically binds to a different one of the three target analytes 310a-c. The first substances each include a different first oligonucleotide 308a-c. As shown in Figure 3A, contacting each of the first substances with the sample results in a sample in which the first substances selectively bind only to the corresponding target analytes 310a-c with which their binding species 306a-c are matched.

[0113] In the next step of the analysis, a second substance, including reactive species 314a and a second oligonucleotide 312a that is at least partially complementary to the first oligonucleotide 308a, is contacted with the sample. As shown in FIG. 3C, the second oligonucleotide 312a hybridizes to the first oligonucleotide 308a, causing the second substance to selectively bind to the first substance bound to the target analyte 310a. Due to the lack of complementarity between the second oligonucleotide 312a and the first oligonucleotides 308b and 308c, the second substance does not bind to either the first substance bound to the target analyte 310b or the first substance bound to the target analyte 310c.

[0114] Thereafter, as shown in Figure 3C, the label 318a contacts the sample and reacts with the reactant 314a in the manner described above to selectively deposit the label 318a (or a derivative thereof) in close proximity to the target analyte 310a. The reaction and deposition of the label 318a is illustrated diagrammatically in Figure 3C by the dashed arrow 320a.

[0115] After deposition of the labeling substance 318a, the second substances (i.e., the second oligonucleotide 312a and the reactant 314a) are removed from the sample 302 by dehybridization and washing as described above. The resulting sample 302 is shown diagrammatically in Figure 3D. Each of the different first substances remains bound to a corresponding different target analyte 310a, and the labeling substance 318a deposited in close proximity to the target analyte 310a also remains bound to the sample 302.

[0116] 3C and described in steps 354-360 of flow chart 350 are then repeated, first with a second substance comprising a second oligonucleotide that selectively hybridizes through at least partial complementarity to the first oligonucleotide 308b of the first substance bound to target analyte 310b, and then with a second substance comprising a second oligonucleotide that selectively hybridizes through at least partial complementarity to the first oligonucleotide 308c of the first substance bound to target analyte 310c. In each cycle, a different labeled substance is contacted with the sample and deposited in close proximity to the corresponding target analyte.

[0117] After three complete labeling cycles, the sample 302 appears as shown diagrammatically in FIG. 3E, with each of the three different first substances remaining bound to their corresponding target analytes 310a-c, and with the three different labeled substances 318a-c remaining deposited in close proximity to each of the three different target analytes 310a-c, respectively.

[0118] Typically, each of the different labeling substances 318a-c may correspond to any of the labeling substances described above. To perform an analysis of multiple target analytes in a sample, the labeling substances are typically selected such that they generate different measurement signals. For example, in embodiments in which each of the labeling substances includes a fluorescent or chromogenic dye moiety, the substances are selected such that each of the dye moieties has different spectral properties (e.g., absorption, emission) such that measurement light emitted from, transmitted through, or reflected from the sample can be separated into contributions from each of the dyes and used to separately identify and quantify each of the target analytes 310a-c in the sample.

[0119] Report Substance Reporting substances can be used in connection with the above methods. Generally, reporting substances include oligonucleotides directly or indirectly conjugated with labeling moieties. Reporting substances used in the methods described herein include oligonucleotides that are at least partially complementary to and hybridize with the corresponding first oligonucleotides of the above first substances. Thus, the oligonucleotides of the reporting substances can generally include any of the features of the first and second oligonucleotides discussed above. Furthermore, reporting substances can include any one or more of the different types of labeling moieties described above.

[0120] The use of a report substance can be incorporated into the procedures described herein at various points and to achieve various purposes. For example, in some embodiments, a report substance can be used to verify the presence of a particular target analyte in a sample. FIG. 4A shows a schematic diagram of a sample 402 that includes three different target analytes 410a-c, similar to sample 302 in FIG. 3A. Three different first substances are selectively bound to sample 302, one each for binding to a respective one of the different target analytes. Each of the first substances includes a binding substance 406a-c and a first oligonucleotide 408a-c.

[0121] Prior to introducing a second substance to the sample 402 (e.g., as in step 354 of flow chart 350), the sample is contacted with a reporting substance 450 to verify the presence of the target analyte 410a in the sample 402. As shown in FIG. 4A, the reporting substance 450 includes a label moiety 454 conjugated to an oligonucleotide 452. The oligonucleotide 452 is at least partially complementary to the oligonucleotide 408a and hybridizes to the oligonucleotide 408a when the reporting substance 450 is introduced to the sample. The nucleotide sequence of the oligonucleotide 452 is sufficiently non-complementary to the sequences of the first oligonucleotides 408b and 408c such that the oligonucleotide 452 does not hybridize to either of these first oligonucleotides. After washing away the unbound reporting substance 450, the remaining reporting substance 450 in the sample 402 selectively binds to the first substance that binds the target analyte 410a.

[0122] The presence of target analyte 410a in sample 402 can be verified by measuring light emitted from, reflected from, or transmitted through sample 402. In particular, by detecting a portion of the measured light that corresponds to label moiety 454, the presence of target analyte 410a in sample 402 can be verified. Optionally, the amount of target analyte 410a in sample 402 can also be quantified based on the measured signal contribution attributable to label moiety 454.

[0123] The location in the sample 402 where the target analyte 410a is present can be used to determine an area of ​​interest for further measurement and / or delivery of a substance to the sample 402. For example, if the target analyte 410a is localized in only a portion of the sample 402, then subsequent sample light emission, reflection, or transmission measurements and / or delivery of a substance to the sample 402 can optionally be limited to only that region of the sample.

[0124] Alternatively, if the target analyte 410a is not present in the sample, the first substance (i.e., having the binding species 406a and the first oligonucleotide 408a) that selectively binds the target analyte 410a will not bind to the sample 402. As a result, the reporting substance 450 will also not bind to the sample 402 due to the absence of the first oligonucleotide 408a, and the measured light from the sample 402 will not include a contribution from the label moiety 454, indicating the absence of the target analyte 410a in the sample. As a result, the step of contacting the sample with the second substance and the label species to specifically deposit the label moiety in close proximity to the target analyte 410a can be omitted.

[0125] In the above example, a single reporting substance 450 is used to selectively identify and optionally quantify a single target analyte 410a in a sample. However, similar labeling and measurement can be performed with multiple different reporting substances, each of which includes a different oligonucleotide and a different label moiety that selectively hybridizes with only one of the first oligonucleotides 408a-c in FIG. 4A such that each reporting substance 450 targets a specific target analyte 410a-c. Each of the reporting substances can be contacted with the sample, measured, and removed sequentially, or alternatively, a group of multiple reporting substances can be applied to the sample. Parallel analysis of two or more (e.g., three or more, four or more, five or more, six or more, eight or more, ten or more, or even more) different target analytes in a sample can be performed, provided that the measured emitted, transmitted, or reflected light from the sample can be resolved into contributions from the respective label moieties of the individual reporting substances.

[0126] Reporting substances may also generally be used at any intermediate step in the analytical procedures described herein. For example, with reference to the procedures described in connection with Figures 3A-3E, reporting substances may be used to verify the presence of any of the target analytes 310a-c (and corresponding target analytes 410a-c in Figure 4A). They may be introduced at any stage in the procedure after contacting the sample with one or more first substances, as described above.

[0127] In some embodiments, a report substance can be used in conjunction with, or as an alternative to, a labeling species to identify and quantify target analytes in a sample. Figure 4B shows a schematic diagram of a sample 402 containing five different target analytes 410a-e. The sample has been contacted with five different first substances, each of which has a different binding species 406a-e and a different first oligonucleotide 408a-e that selectively binds each of them to one of the five different target analytes.

[0128] Three analytical cycles, as generally described above, are also performed on the sample 402 in Figure 4B to deposit label moieties in close proximity to the three different target analytes, resulting in three different label species 418a-c being deposited in the sample in close proximity to respective target analytes 410a-c.

[0129] Additionally, two different reporter substances are introduced into the sample. The first of the reporter substances includes an oligonucleotide 452d and a label moiety 454d. The oligonucleotide 452d is at least partially complementary to the first oligonucleotide 408d and hybridizes with the first oligonucleotide 408d. The oligonucleotide 452d is not sufficiently complementary to any of the other first oligonucleotides in the sample to significantly hybridize with the other first oligonucleotides. Similarly, the oligonucleotide 452e of the second reporter substance is at least partially complementary to the first oligonucleotide 408e and hybridizes with the first oligonucleotide 408e. The oligonucleotide 452e is not sufficiently complementary to any of the other first oligonucleotides in the sample 402.

[0130] The label moieties in the label species 418a-c and the report substances (i.e., label species 454d-e) are selected such that each label species is different and therefore has different spectral absorption, reflection, or emission characteristics. By analyzing the emitted, transmitted, or reflected light from the sample 402, the contributions from each of the different label moieties can be distinguished and selectively attributed to the target analytes 410a-e. In this manner, each of the target analytes 410a-e in the sample 402 can be identified and quantified.

[0131] The sample 402 in Figure 4B contains a mixture of labeling moieties from the labeling species and the reporter substance, however, in some embodiments, the reporter substance can be used to label and detect signals corresponding to all of the target analytes in a biological sample.

[0132] For example, Figure 4C is a schematic diagram of a sample 402 that includes M different target analytes 410a...410M, where M can generally be 2 or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 8 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, or even greater). The sample is contacted with a set of first substances 410a...410M, as described above, such that each one of the first substances selectively binds to a different one of the M target analytes.

[0133] Reporting substances 450a...450M are then selectively hybridized with the first substance to label the M target analytes. Each reporting substance includes a different label moiety such that each of the M target analytes is labeled with a different label moiety. In some embodiments, the reporting substances are applied one at a time (i.e., sequentially) to the sample 402 and light emitted, reflected, or transmitted from the sample with only one of the reporting substances present at a time is measured to identify and quantify the target analyte corresponding to that one reporting substance.

[0134] However, in certain embodiments, the sample is contacted with a group of reporter substances (e.g., a group of two or more reporter substances, a group of three or more reporter substances, a group of four or more reporter substances, a group of five or more reporter substances, a group of six or more reporter substances, a group of eight or more reporter substances, or even a group of even more reporter substances), where each reporter substance selectively hybridizes to only one of the first substances bound to one of the target analytes in the sample. Light emitted, reflected, or transmitted from a sample having multiple reporter substances of a group present in the sample is measured and resolved into contributions from each of the label moieties of the reporter substances. These contributions can then be used to identify and quantify each of the target analytes corresponding to the reporter substances of the group.

[0135] The group of reporter substances can then be removed from the sample by dehybridization, as previously discussed, and a new group of reporter substances is introduced that selectively hybridize to a different set of first substances bound to a different set of target analytes. The new group can contain the same number of reporter substances or a different number of reporter substances compared to the previous group.

[0136] Analysis of the target analytes in the sample continues in this manner, with successive groups of reporter substances being hybridized, detected and removed until all M target analytes have been analyzed.

[0137] In some embodiments, a hybrid analytical workflow can be implemented that uses both report substances and deposition of labeling moieties (e.g., by TSA) to analyze target analytes. Such procedures can be used, for example, for samples that contain a relatively large number of target analytes, some of which (e.g., between 1 and 8 of them) are of particular interest. Hybrid procedures are also useful for samples that contain a relatively large number of target analytes, some of which are weakly expressed or produce signals after labeling that are otherwise difficult to measure. Amplification of measurement signals corresponding to particularly important or weakly expressed target analytes can be used to achieve highly multiplexed sample characterization with special attention to certain analytes.

[0138] An example of such a sample 402 is shown in Figure 4D. The sample includes target analytes 410a ... 410M, as well as 410u, 410v, and 410w. Among these target analytes, 410u-410w are of particular interest.

[0139] An example of a hybrid analysis workflow is as follows: A sample 402 is contacted with first substances 404a...404M and 404u-404w, each of which comprises a different binding group that selectively binds to one of the target analytes, and a different first oligonucleotide.

[0140] After the first substances selectively bind to their respective target analytes and localize to their corresponding locations in the sample 402, the target analytes 410a...410M are analyzed with the report substances 450a...450M in the manner described above with respect to FIG. 4C. Specifically, the report substances hybridize to the first substances in the sample 402, either in groups or individually. Each report substance comprises a different oligonucleotide that is at least partially complementary to only one of the first oligonucleotides of the first substances 404a...404M, and a different label moiety. The report substances 450a...450M can hybridize to the sample one at a time (e.g., sequentially) or in groups of two or more. To detect the report substances after hybridization, the light emitted, reflected, or transmitted from the sample is measured and, if it includes contributions from multiple label moieties, is resolved into contributions from each of the label moieties. The target analytes corresponding to each group of reporter substances are identified and optionally quantified, after which the groups of reporter substances are removed from the sample 402 by dehybridization and washing. Analysis of the remaining target analytes 410a...410M is performed in a similar manner by hybridizing one or more groups of selective reporter substances with corresponding first substances 404a...404M, measuring the signal corresponding to the reporter substances, and then removing the reporter substances in preparation for another analysis cycle.

[0141] Each of the target analytes of interest 410u-410w is then analyzed in a similar manner. As shown diagrammatically in FIG. 4E, the sample is contacted with a second material comprising a second oligonucleotide 412u that selectively hybridizes with the first oligonucleotide 408u. Conjugated to the second oligonucleotide 412u is a reactive species 414u. After hybridization of the second material, a labeled species 418u contacts the sample and reacts with the reactive species 414u, depositing the labeled species 418u (or a derivative thereof) at a location in the sample proximate to the target analyte 410u. After deposition of the labeled species 418u, the second material (e.g., comprising the second oligonucleotide 412u and the reactive species 414u) is removed from the sample by dehybridization and washing.

[0142] To analyze a target analyte 410u, light emitted, reflected or transmitted from the sample is measured and the contribution to the measured signal from the labeled species 418u is determined to identify and optionally quantify the target analyte 410u.

[0143] The sequence of steps described above for analyzing target analyte 410u is then repeated to analyze target analytes 410v and 410w, using a second substance that includes a different second oligonucleotide that specifically hybridizes to the first substance that specifically binds to target analytes 410v and 410w. In the example shown in Figures 4D and 4E, two additional cycles of the sequence of steps described for target analyte 410u are performed to analyze target analytes 410v and 410w, respectively.

[0144] Kits and Compositions The substances, species, and moieties described herein can be included in various kits that feature compositions that include the substances, species, and moieties. Generally, a kit is a package of one or more reagents, each in the form of a composition. Compositions that feature any of the different substances, species, and moieties described herein can be prepared and used for target analyte analysis as described herein. These compositions can be included in product kits, along with other features such as instructions for preparing the compositions and using the compositions in sample analysis. Product kits can be sealed or otherwise contained in a variety of different containers.

[0145] Measuring an optical signal corresponding to the labeling moiety FIG. 6 is a schematic diagram illustrating a system 600 for acquiring multiple spectrally resolved images of a sample. The system 600 can measure light emitted, transmitted, and / or reflected from a sample containing one or more of the labeling moieties described herein. The measured light generally includes a contribution from each of the labeling moieties present in the sample, and the system 600 can analyze the encoded multispectral image information in the measured light and decompose the image information to isolate the contribution to the measured light from each of the labeling moieties in the sample. The decomposition produces a set of amplitude or intensity measurements for each labeling moiety in the sample as a function of position within the sample. The amplitude or intensity measurements can be used to quantify the amount of each labeling moiety, and therefore the amount of each target analyte, at each location in the sample.

[0146] The light source 602 provides light 622 to the light conditioning optics 604. The light 622 can be incoherent light, such as light generated from a filament source, or the light 622 can be coherent light, such as light generated by a laser. The light 622 can be either continuous wave (CW) or time-gated (i.e., pulsed) light. Furthermore, the light 622 can be provided in a selected portion of the electromagnetic spectrum. For example, the light 622 can have a central wavelength and / or a distribution of wavelengths that fall within the ultraviolet, visible, infrared, or other regions of the spectrum.

[0147] The light conditioning optics 604 may be configured to transform the light 622 in some manner. For example, the light conditioning optics 604 may spectrally filter the light 622 to provide output light in a selected wavelength region of the spectrum. Alternatively or additionally, the light conditioning optics may adjust the spatial distribution of the light 622 and the temporal characteristics of the light 622. The incident light 624 is generated from the light 622 by action of the elements of the light conditioning optics 604.

[0148] The incident light 624 is directed to impinge on a sample 608 mounted on an illumination stage 606. The stage 606 can provide a means for securing the sample 608, such as a mounting clip or other fastening device. Alternatively, the stage 606 can include a movable track or belt to which multiple samples 608 are affixed. The driver mechanism can be configured to move the track to translate the multiple samples, one at a time, in sequence through an illumination area on the stage 606 upon which the incident light 624 acts. The stage 606 can further include a translation axis and mechanism for translating the sample 608 relative to a fixed position on the illumination stage 606. The translation mechanism can be manually operated (e.g., a threaded rod) or can be automatically movable by a motorized drive (e.g., a motorized driver, a piezoelectric actuator).

[0149] In response to the incident light 624, emitted light 626 emerges from the sample 608. The emitted light 626 can be generated in a number of ways. For example, in some embodiments, the emitted light 626 corresponds to a portion of the incident light 624 transmitted through the sample 608. In other embodiments, the emitted light 626 corresponds to a portion of the incident light 624 reflected from the sample 608. In still further embodiments, the incident light 624 can be absorbed by the sample 608, and the emitted light 626 corresponds to fluorescent emission from the sample 608 (e.g., from a fluorescent component in the sample 608) in response to the incident light 624. In yet further embodiments, the sample 608 can be luminescent and can produce emitted light 626 even in the absence of the incident light 624. In some embodiments, the emitted light 626 can include light produced by two or more of the aforementioned mechanisms.

[0150] The light collection optics 610 are positioned to receive the emitted light 626 from the sample 608. The light collection optics 610 may be configured to collimate the emitted light 626, for example, if the light 626 is diverging. The light collection optics 610 may also be configured to spectrally filter the emitted light 626. Filtering operations may be useful, for example, to isolate a portion of the emitted light 626 caused by one of the mechanisms discussed above from light caused by other processes. For example, the methods described herein may be used to determine an accurate estimate of the fluorescence spectrum of one or more labeled moieties in a sample. The light collection optics 610 may be configured to filter out non-fluorescent components of the emitted light 626 (e.g., components corresponding to transmitted and / or reflected incident light). Additionally, the light collection optics 610 may be configured to modify the spatial and / or temporal characteristics of the emitted light 626 for a particular purpose in an embodiment. The light collecting optics 610 convert the emitted light 626 into output light 628 that is incident on the detector 612 .

[0151] Detector 612 includes one or more elements, such as a CCD sensor, configured to detect output light 628. In some embodiments, detector 612 may be configured to measure spatial and / or temporal and / or spectral characteristics of light 628. Detector 612 generates an electrical signal corresponding to output light 628 and communicated to electronic control system 614 via electrical communication line 630.

[0152] The electronic control system 614 includes a processor 616, a display device 618, and a user interface 620. In addition to receiving signals corresponding to the output light 628 detected by the detector 612, the control system 614 sends electrical signals to the detector 612 to adjust various characteristics of the detector 612. For example, if the detector 612 includes a CCD sensor, the control system 614 may send electrical signals to the detector 612 to adjust the exposure time, active area, gain settings, and other characteristics of the CCD sensor.

[0153] The electronic control system 614 also communicates with the light source 602, the light conditioning optics 604, the illumination stage 606, and the light collecting optics 610 via electrical communication lines 632, 634, 636, and 638, respectively. The control system 614 provides electrical signals to each of these elements of the system 600 to adjust various properties of that element. For example, electrical signals provided to the light source 602 can be used to adjust the intensity, wavelength, repetition rate, or other properties of the light 622. The signals provided to the light conditioning optics 604 and the light collecting optics 610 can include signals for setting properties of devices that adjust the spatial properties of the light (e.g., spatial light modulators) and for setting spectral filtering devices. The signals provided to the illumination stage 606 can provide, for example, for positioning the sample 608 relative to the stage 606 and / or moving the sample to a position for illumination on the stage 606.

[0154] The control system 614 includes a user interface 620 for displaying system characteristics and parameters, as well as for displaying captured images of the sample 608. The user interface 620 is provided to facilitate operator interaction with and management of the system 600. The processor 616 includes a memory device for storing image data captured using the detector 612, and also includes computer software that embodies instructions to the processor 616 that cause the processor 616 to perform control functions, such as those discussed above. In addition, the software instructions cause the processor 616 to mathematically manipulate the images captured by the detector 612, and to perform steps to decompose images acquired by the system 600 into contributions from specific labeled species in the sample.

[0155] In some embodiments, the light conditioning optics 604 includes an adjustable spectral filter element, such as a filter wheel or liquid crystal spectral filter. The filter element can be configured to provide illumination of the sample using different light wavelength bands. The light source 602 can provide light 622 having a broad distribution of spectral wavelength components. Selected regions of this broad wavelength distribution are permitted to pass as incident light 624 by the filter elements in the light conditioning optics 604 and directed to impinge on the sample 608. The wavelengths of the filter passbands in the light conditioning optics 604 are subsequently altered to provide incident light 624 having different wavelengths. Spectrally resolved images can also be recorded by using a light source 602 with multiple source elements generating light of different wavelengths, and alternatively, by switching different source elements on and off to provide incident light 624 having different wavelengths.

[0156] The light collecting optics 610 may include configurable spectral filter elements similar to those discussed above in connection with the light conditioning optics 604. Thus, spectral resolution may be provided on the excitation side of the sample 608 (e.g., by the light conditioning optics 604) and on the emission side of the sample 608 (e.g., by the light collecting optics 210).

[0157] The result of collecting multiple, spectrally resolved images of a sample is an "image stack," which is a two-dimensional image of the sample, with each image in the stack corresponding to a particular wavelength. Conceptually, the set of images can be visualized to form a three-dimensional matrix, where two of the matrix dimensions are the spatial length and width of each of the images, and the third matrix dimension is the spectral index. For this reason, a set of spectrally resolved images can be referred to as a "spectral cube" of images. As used herein, a "pixel" in such a set of images (or image stack or spectral cube) refers to a common spatial location for each of the images. Thus, a pixel in an image set contains a value associated with each image at the spatial location corresponding to that pixel.

[0158] Spectral unmixing methods can be used to isolate the contributions from each of the multiple labeling species in a sample to the image information contained in a multispectral image stack. Spectral unmixing is a technique that quantitatively separates the contributions in an image that originate from spectrally distinct sources. For example, a sample may contain three different types of target analytes, each labeled with a labeling species. Each of the three different labeling species may have a different absorption spectrum. Typically, the individual absorption spectra of the labeling species are known before they are used or before they can be measured. An image of a sample under illumination will most commonly contain spectral contributions from each of the three labeling species. A similar situation occurs in a sample that contains, for example, multiple different fluorescently labeled species, each of which contributes to the measured fluorescent emission.

[0159] Spectral unmixing decomposes one or more images containing contributions from multiple spectral sources into a set of component images ("unmixed images") that correspond to the contributions from each of the spectral entities in the sample. Thus, if a sample contains three different labeling species, each specific for a particular target analyte, the image of the sample can be separated into three unmixed images, where each unmixed image primarily reflects the contribution from only one of the dyes.

[0160] The unmixing procedure essentially corresponds to decomposing an image into a set of spectral eigenstates. In many embodiments, the eigenstates are known in advance, as discussed above. In other embodiments, the eigenstates may be determined using techniques such as principal component analysis. In either case, once the eigenstates have been identified, the image may be decomposed by calculating a set of values, typically a coefficient matrix, corresponding to the relative weighting of each of the eigenstates in the overall image. The contributions of each of the individual eigenstates may then be separated to yield an unmixed image set.

[0161] As an example, a series of two-dimensional images having x and y coordinates may be imaged at a set of different excitation wavelengths λ k As mentioned above, the two-dimensional images can be combined to form a three-dimensional image cube I(x,y,k), where the first two indices of the image cube represent the coordinate directions and the third index is a spectral index corresponding to the wavelength of the illuminating light. For simplicity, let each of the images of the sample be illuminated by two different spectral sources F(λ k ) and G(λ k ), the values ​​in the 3D image cube I(x,y,k) can be given by: S(x,y,k)=a(x,y)·F(λ k )+b(x,y)·G(λ k ) (1) In the formula, λk is used to denote a given wavelength (or wavelength range). The functions a(x,y) and b(x,y) describe the spatial abundance of the spectral contributions from two different spectral sources in the sample.

[0162] According to equation (1), the net signal at any location in the 3D image cube (i.e., at any 2D pixel coordinate and at a particular illumination wavelength) is the sum of the two contributions weighted by their relative abundance. This can be expressed as: I(λ k )=aF(λ k )+bG(λ k ) (2)

[0163] The functions F and G can be termed the "spectral eigenstates" for the system because they correspond to the pure spectra for the spectral sources in the sample, which are combined in various proportions to produce the measured spectral image of the sample. The sample spectrum is thus a weighted superposition corresponding to the separate contributions from the two spectral sources.

[0164] Spectrum F(λ k ) and G(λ k ), equation (2) can be expressed as: k (provided we have data for a, b), we can invert it to solve for a and b. Equation (2) can be rewritten in matrix form as I=EA, resulting in: A=E -1 I (3) where A is a column vector with entries a and b, and E is a matrix whose columns are the spectral eigenstates, i.e., [FG].

[0165] Using equation (3), the measured spectral image of the sample can be used to calculate, at a particular pixel location, the contribution to the image that arises purely from source F and the contribution to the image that arises purely from source G. The process can be repeated for each pixel location in the selected image (i.e., over a range of values ​​x and y in I) to produce an image of the sample that includes contributions only from source F, and another image of the sample that includes contributions only from source G.

[0166] In the above discussion, the number of spectral sources is 2 (i.e., F and G). However, in general, the unmixing technique is not limited to any particular number of sources. For example, a sample may generally contain m different spectral sources. If the number of wavelengths at which data is collected is n, i.e., k=1...n, then the matrix E is an nxm matrix instead of an nx2 matrix as in the above discussion. The unmixing algorithm can then be used in the same manner as above to isolate the specific contributions at each pixel location in the image from each of the m spectral eigenstates.

[0167] One factor that may limit the ability of an algorithm to distinguish between contributions from different spectral eigenstates is the degree of spectral discrimination between the eigenstates. The correlation between two spectra, such as two spectral eigenstates I1 and I2, can be described by the spectral angle θ as follows:

[0168]

number

[0169] A set of spectra where θ is small for two members is not easily separated into its components. Physically, the reason for this is easy to see: if two spectra are only marginally different, it is more difficult to determine the relative abundance of each.

[0170] Several techniques can be used to measure or estimate the pure spectra of the spectral sources F and G (and other spectral sources if the sample contains more than two). In general, any method that produces spectral eigenstates of sufficient accuracy can be used. Some samples may contain spectral sources such as dyes or other chemical moieties that have known spectra available in published references. Alternatively, it may be possible to measure the spectra of the source components directly using one or more measurement systems. In some samples, it may be known that a particular region of the sample contains only one particular spectral source, and the spectrum of that source can be extracted from measurements made only on the identified region of the sample.

[0171] Various data analysis techniques can also be used to determine the component spectra as spectral unmixing, for example, Principal Component Analysis (PCA), which identifies the most orthogonal spectral eigenvectors from the image cube and generates a score image that indicates the weighting of each eigenvector throughout the image. This may be performed in combination with other mathematical processes, such as projection pursuit, and other known techniques for identifying low-dimensional spectral vectors, such as the technique described in L. Jimenez and D. Landgrebe, "Hyperspectral Data Analysis and Feature Reduction Via Projection Pursuit," IEEE Transactions on Geoscience and Remote Sensing, Vol. 37, No. 6, pp. 2653-2667, November 1999, the entire contents of which are incorporated herein by reference. Other techniques include, for example, Independent Component Analysis (ICA) and endmember detection algorithms.

[0172] These techniques are typically not well suited for applications in life sciences. For example, some techniques are optimized for spectral image datasets that contain spectra with dense spectral features and well-defined narrow peaks. In some techniques, the spectral range is large compared to the individual spectral features and peaks used in the analysis. The presence of peaks or the ratio of peaks can then be used to classify the "endmembers" to be separated. Unfortunately, components in biological samples typically do not have such well-defined narrow peaks.

[0173] Some of these techniques produce images related to spectra present in pure form somewhere within the initial image cube. In many cases in life sciences, the signal spectra present in the image cube are mixtures of components. If the component of interest is not present in pure form somewhere within the initial image cube, these techniques are unlikely to produce an image that accurately represents the abundance of the component of interest.

[0174] There are several techniques, sometimes called "convex-hull" algorithms, that estimate what the true endmembers are even when they are not present in pure form in the image, but their effectiveness depends on how close the signal spectrum in the image cube is to the endmembers.

[0175] One technique that can be used to extract the spectral eigenstates (or a representation thereof) even in the absence of a priori knowledge of all of the eigenstates is to calculate the signal spectrum I(λ) for a given pixel. k ) and leaving the remaining signal positive definite in all spectral channels, the first spectral source F(λ k ) from it. That is, for each pixel we obtain the so-called "remainder spectrum" U a (λ k ) to define: Ua (λ k )=I(λ k )-aF(λ k ) (5) Then, U has non-negative values ​​in all spectral channels. a (λ k ) and select the maximum value of the parameter a that is consistent with the a (λ k ) is used as the signal spectrum with the contribution from the first spectral source F erased. The determination of the parameter a may also be based on some related criterion that incorporates a small negative distribution to account for considerations such as shot noise or detector noise in the measurement system, rather than on the strict non-negativity criterion listed above. Additional examples of optimization criteria for removing the largest amount of spectral source F include using a different error function.

[0176] Alternatively, one may seek to extract the contribution to the measured spectrum due to a second spectral source G. Similar to equation (5), the residual spectrum can be calculated for each pixel as follows: U b (λ k )=I(λ k )-bG(λ k ) (6) However, U has non-negative values ​​in all spectral channels. b (λ k ) and choose the maximum value of parameter b that is consistent with

[0177] The residual technique can be extended to cases where the spectra for one or more additional components of the sample are known and one wishes to remove their signal contributions, in which case the residual spectrum is expressed based on the additional spectra and by subtracting the contribution of each such component from the observed signal, consistent with a positive residual in each spectral channel.

[0178] Additional aspects of spectral unmixing are described in US Pat. Nos. 10,126,242 and 7,555,155, and PCT Patent Publication No. WO2005 / 040769, the entire contents of each of which are incorporated herein by reference.

[0179] 7 illustrates an example of an electronic control system 614 that may be used with the systems and methods disclosed herein. The electronic control system may include one or more processors 702 (e.g., corresponding to processor 616 in FIG. 6), memory 704, storage device 706, and an interface 708 for interconnection. Processor 702 may process instructions for execution within electronic control system 614, including instructions stored in memory 704 or storage device 706. For example, the instructions may direct processor 702 to perform any of the analyses and control processes disclosed herein.

[0180] The memory 704 can store executable instructions for the processor 702, information about system parameters such as excitation and detection waves, and measured spectral image information. The storage device 706 can be a computer readable medium such as a floppy disk device, a hard disk device, an optical disk device, or a series of devices including a tape device, a flash memory or other similar solid state memory device, or a device in a storage area network or other configuration. The storage device 706 can store any of the instructions that can be executed by the processor 702 described above, and other information that can be stored by the memory 704.

[0181] In some embodiments, the electronic control system 614 may include a graphics processing unit for displaying graphical information (e.g., using a GUI or text interface) on an external input / output device such as a display 716. The graphical information may be displayed by a display device (e.g., a CRT (cathode ray tube) or LCD (liquid crystal display) monitor) for displaying any of the information disclosed herein, such as measured and calculated spectra and images. A user may use an input device (e.g., a keyboard, pointing device, touch screen, voice recognition device) to provide input to the electronic control system 614.

[0182] The methods disclosed herein can be implemented by electronic control system 614 (and processors 702 and 616) by executing instructions in one or more computer programs executable and / or interpretable in electronic control system 614. These computer programs (also known as programs, software, software applications, or code) include machine instructions for a programmable processor and can be implemented in high-level procedural and / or object-oriented programming languages ​​and / or assembly / machine languages. For example, a computer program may contain instructions that can be stored in memory 704, storage device 706, and / or a tangible computer-readable medium, as described above, and executed by processor 702 (processor 616). As used herein, the term "computer-readable medium" refers to any computer program product, apparatus, and / or device (e.g., magnetic disks, optical disks, memories, programmable logic devices (PLDs), ASICs, and electronic circuits) used to provide machine instructions and / or data to a programmable processor, including machine-readable media that receive machine instructions.

[0183] In general, the electronic control system 614 can be implemented in a computing system to perform the above operations. For example, the computing system can include a back-end component (e.g., as a data server), or a middleware component (e.g., an application server), or a front-end component (e.g., a client computer with a graphical user interface), or any combination thereof.

[0184] Reagents and conditions Generally, the various steps described herein can be carried out under a wide variety of conditions and using different reagents, and therefore, it should be understood that the reagents and conditions described in this section only represent examples of suitable reagents and conditions.

[0185] Typically, the first substance can be prepared and stored in a buffer solution that can include one or more of PBS, PBS-T, TBS, TBS-T, water, saline, and Krebs buffer. The buffer solution can optionally include one or more blocking materials. Examples of suitable blocking materials include, but are not limited to, BSA, casein, sheared salmon sperm DNA, oligonucleotides, rat IgG antibodies, and mouse IgG antibodies.

[0186] The second substance can also be prepared and then stored in a buffer solution. The buffer can include one or more of PBS, PBS-T, TBS, TBS-T, water, saline, and Krebs buffer. The buffer solution can be the same or different from the buffer solution used to store the first substance.

[0187] To promote hybridization between the first and second substances and / or between the first and report substances, the first and second substances (or the first and report substances) may be immersed in a hybridization buffer. A suitable hybridization buffer may contain a DNA component, a protein component, a surfactant, and / or a chaotropic agent at a concentration between 5% and 20%.

[0188] To facilitate dehybridization between the first and second substances and / or the first and report substances, the first and second substances (or the first and report substances) may be immersed in a dehybridization buffer. A suitable dehybridization buffer may contain a chaotropic agent, such as DMSO and / or formamide, at a concentration between 60% and 90%.

[0189] To promote binding of the first substance to the target analyte in the sample, the first substance can be layered, e.g., by pipetting, onto the sample in solution and incubated with the sample. After incubation, unbound first substance can be washed from the sample with a buffer solution including, e.g., one or more of PBS, PBS-T, TBS, TBS-T, water, saline, and Krebs buffer.

[0190] Incubation times for any of the hybridization, reaction, binding, and dehybridization steps described herein can be 10 minutes or more (e.g., 20 minutes or more, 30 minutes or more, 40 minutes or more, 60 minutes or more, 1 hour or more, 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 6 hours or more, 8 hours or more, 10 hours or more, 16 hours or more, 20 hours or more, 24 hours or more, 48 hours or more, 7 days or more, 30 days or more). EXAMPLES

[0191] To demonstrate the efficacy of the method described herein for analyzing multiple target species in biological samples, several studies were performed. First, FFPE samples of human tonsil tissue were obtained. In the first labeling and imaging cycle, the tissue sample was labeled with a first agent, which included an antibody binding agent that specifically targets the biomarker PD-1. A second agent was then incubated with the sample and hybridized with the first agent. The second agent included an HRP moiety conjugated to an oligonucleotide. A labeling agent containing a labeling moiety (OPAL® dye HX0046, available from Akoya Biosciences, Inc., Menlo Park, CA) was deposited in the tissue sample by HRP-mediated TSA. After removal of the second agent, the sample was imaged to reveal the presence of PD-1.

[0192] Two further analytical cycles were performed. In the second cycle, the sample was labeled with a first material comprising an antibody binding substance specifically targeting the biomarker PDL1, and a labeling moiety (OPAL® dye HX043, available from Akoya Biosciences, Inc.) was deposited by HRP-mediated TSA to label PDL1. In the third cycle, the sample was labeled with a first material comprising an antibody binding substance specifically targeting the biomarker FOXP3, and a labeling moiety (OPAL® dye HX031, available from Akoya Biosciences, Inc.) was deposited by HRP-mediated TSA to label FOXP3.

[0193] Figures 8A-8C are images showing the distribution and relative concentrations of the biomarkers PD-1, PDL1, and FOXP3, respectively, in a tissue sample. Figure 8D is an overlay image showing the distribution of all three markers within the sample. As is evident from the images, each of the different biomarkers could be independently identified and quantified in the sample, with little or no cross-channel interference if the applied labeling moieties were appropriately selected.

[0194] To investigate the effect of HRP-mediated TSA amplification, human FFPE sections of tonsil tissue were obtained and more than 15 different first substances (each containing a binding substance targeting a different biomarker) were bound to the sample. Corresponding reporting substances were then hybridized to the first substances, and images of the sample with different subsets of reporting substances were obtained. The reporting substances were then removed from the sample by dehybridization as described above, and labeling moieties targeting three different markers, namely PD-1, PDL-1, and FOXP3, were deposited in the sample in three separate HRP-mediated TSA labeling cycles. Images of the sample with amplified signals corresponding to the markers PD-1, PDL-1, and FOXP3 were then obtained.

[0195] FIG. 9A is an image showing the distribution and relative concentration of the markers CD8, CD31, CD20, CD45RO, CD4, pancytokeratin, and CD34 in tissue sections, and FIG. 9B is an image showing the distribution and relative concentration of CD11c, Ki67, PDL-1, E-cadherin, CD3, and FOXP3 in tissue sections. The amplified signals due to PD-1, PDL-1, and FOXP3 are shown in the image of FIG. 9C. The signals corresponding to PDL-1 and FOXP3 in FIG. 9C are significantly more intense than the corresponding signals for these markers in FIG. 9B. The nucleotide sequences corresponding to the first agent (first oligonucleotide), the report agent, and the second agent (second oligonucleotide) are shown in Table 1 below.

[0196] [Table 1]

[0197] To demonstrate the removal of the second substance from the sample, FFPE sections of tonsil tissue were obtained and subjected to three cycles of HRP-mediated TSA to deposit the labeled moiety. In the first cycle, OPAL® dye 570 (Akoya Biosciences, Inc.) was deposited in the sample by HRP-mediated TSA. The second substance was then removed from the sample, and a second cycle was performed by introducing OPAL® dye 690 (Akoya Biosciences, Inc.) without hybridizing the second substance, and therefore without the presence of HRP reactive agent in the sample. In the third cycle, OPAL® dye 690 was deposited by HRP-mediated TSA. After the second and third cycles, sample images were obtained.

[0198] Figures 10A and 10D show nuclear staining images after cycles 2 and 3, Figures 10B and 10E show OPAL® Dye 570 images after cycles 2 and 3, and Figures 10C and 10F show OPAL® Dye 690 images after cycles 2 and 3. As can be seen from Figures 10C and 10F, complete removal of the second material was achieved between cycles 1 and 2.

[0199] For the above example, the labeling protocol for OPAL® dyes 570 and 670 was as follows: (a) The tissue is washed three times with 20% DMSO. (b) The tissue is incubated with 200 μl of hybridization buffer for 10 minutes. After 10 minutes, the tissue is washed 3× with 20% DMSO, followed by 3× with 1× CODEX® Assay Buffer. (c) Add 200 μl of OPAL® dye (O570 or O670) diluted 1:200 and 1:400 in 1×plus Amplification Diluent Reagent, respectively. Incubate for 20 minutes. (d) After 20 minutes, tissues are washed (3x) with 1x CODEX® Assay Buffer, washed (3x) with DI water, and imaged with a 20x objective.

[0200] The labeling protocol for OPAL® dye 780 was as follows: (a) The tissue is washed 3 times with 20% DMSO. The tissue is incubated with 200 μl of hybridization buffer for 10 minutes. After 10 minutes, the tissue is washed (3×) with 20% DMSO, followed by 3× washing with 1× CODEX® Assay Buffer. (b) Add 200 ul of TSA dig diluted 1:50 in 1x plus Amplification Diluent Reagent. Incubate for 15 minutes. (c) After 15 minutes, the tissue is washed with 1× CODEX® Assay Buffer. (d) Add 200ul of OPAL 780 diluted 1:50 in 1x plus Amplification Diluent Reagent. Incubate for 1 hour. Wash tissue with 1x CODEX® Assay Buffer (3x). Rinse with DI water (3x) and image with a 20x objective.

[0201] Other embodiments Although this disclosure describes specific implementations, these should not be construed as limitations on the scope of the disclosure, but rather as descriptions of features in a particular embodiment. Features that are described in the context of separate embodiments can also generally be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable subcombination. Furthermore, although features may be described above as being present in a particular combination and may even initially be claimed as such, one or more features from a claimed combination can generally be deleted from that combination, and the claimed combination may be directed to a subcombination or variation of the subcombination.

[0202] In addition to the embodiments specifically disclosed herein, it will be understood that various modifications to the described embodiments can be made without departing from the spirit and scope of the present disclosure. Accordingly, other embodiments are within the scope of the following claims. [Explanation of symbols]

[0203] 100 Flowchart 202 Biological samples 204 First Substance 206 Combined species 208 First Oligonucleotide 210 Target Analyte 212 Second Oligonucleotide 214 Reactive species 216 Second Substance 218 Marked species 302 Sample 306a~c Combined species 308a-c first oligonucleotide 310a~c Target Analyte 312a Second Oligonucleotide 314a Reactive species, reactants 318a~c Labeled substances 320a dashed arrow 350 Flowchart 402 Sample 404a~M, 404u~w First substance 406a~e Binding substance, binding species 408a-e, 408u First oligonucleotide 410a~M, 410u~410w target analyte 412u Second Oligonucleotide 414u Reactive species 418a~c, 418u marked species 450 Report Substances 450a~M Reporting Substances 452 Oligonucleotides 452d Oligonucleotide 452e Oligonucleotide 454 Sign part 454d~e Mark part, mark species 502 Double-stranded region 504 Single-stranded region 506 Secondary oligonucleotide strands 508 Major Oligonucleotide Strand 510 Intermediate join area 510a Join area 510b Combined area 512a Unbonded region 512b Unbonded region 600 System 602 Light source 604 Light Adjusting Optical Element 606 Lighting stand 608 Samples 610 Light collecting optical elements 612 Detector 614 Electronic Control System 616 processor 618 Display Devices 620 User Interface 622 light 624 Incident light 626 Synchrotron Radiation 628 Output Light 630 Telecommunications Lines 632 Telecommunications Line 634 Telecommunications Lines 636 Telecommunications Lines 638 Telecommunications Lines 702 Processor 704 Memory 706 Storage device 708 Interface 716 Display

Claims

1. The process is as follows: (i) contacting a biological sample containing a first target analyte with a first substance, said first substance comprising a first binding species that specifically binds to said first target analyte and a first oligonucleotide conjugated to said binding species; (ii) contacting the biological sample with a second substance comprising a first reactive species and a second oligonucleotide conjugated to the first reactive species to hybridize at least a portion of the second oligonucleotide to at least a portion of the first oligonucleotide; (iii) contacting the biological sample with a first labeled species, wherein the first labeled species reacts with the first reactive species to deposit the first labeled species or a derivative thereof in the biological sample; (iv) removing the second material from the biological sample after deposition of the first labeled species or a derivative thereof; (v) contacting the biological sample with a third substance, the third substance comprising a second binding species that specifically binds to a second target analyte in the biological sample and a third oligonucleotide conjugated to the second binding species; (vi) contacting the biological sample with a fourth agent comprising a second reactive species and a fourth oligonucleotide conjugated to the second reactive species to hybridize at least a portion of the fourth oligonucleotide to at least a portion of the third oligonucleotide; (vii) contacting the biological sample with a second labeled species, which reacts with the second reactive species to deposit the second labeled species or a derivative thereof in the biological sample. The method includes:

2. The method of claim 1 , wherein the first reactive species comprises a catalytic material.

3. The method of claim 1 , wherein the first reactive species comprises an enzyme.

4. The method of claim 3, wherein the enzyme comprises horseradish peroxidase.

5. The method of claim 1 , wherein the first labeling species comprises a dye.

6. The method of claim 4, wherein the first labeling species comprises a conjugate of an inactive tyramide or a derivative thereof and a dye.

7. 7. The method of claim 6, wherein the step of contacting the biological sample with the first labeled species comprises converting the first labeled species into a conjugate of an active tyramide or a derivative thereof and a dye, wherein the active tyramide or a derivative thereof binds to the biological sample in close proximity to a second substance.

8. The method of claim 1 , wherein the first binding species comprises an antibody or an antibody fragment.

9. 2. The method of claim 1, wherein the first oligonucleotide comprises at least 10 nucleotides.

10. The method of claim 1, wherein the second oligonucleotide comprises at least 10 nucleotides.

11. 2. The method of claim 1, wherein the nucleotide sequences of the first and second oligonucleotides are at least 70% complementary.

12. 2. The method of claim 1, wherein the second oligonucleotide comprises a greater number of nucleotides than the first oligonucleotide.

13. 2. The method of claim 1, wherein the second oligonucleotide comprises multiple contiguous, non-contiguous nucleotide sequences that are complementary to different portions of the sequence of the first oligonucleotide.

14. The method of claim 1 , wherein the first and second reactive species are the same.

15. The method of claim 1 , wherein each of the first and second reactive species comprises an enzyme.

16. 10. The method of claim 1, wherein the first and second reactive species each comprise horseradish peroxidase.

17. The method of claim 1 , wherein the first oligonucleotide and the third oligonucleotide are different.

18. The method of claim 1 , wherein the second oligonucleotide and the fourth oligonucleotide are different.

19. 2. The method of claim 1, wherein the first labeled species comprises a first dye and the second labeled species comprises a second dye that is different from the first dye.

20. 2. The method of claim 1, wherein the first binding species comprises a first antibody or a first antibody fragment and the second binding species comprises a second antibody or a second antibody fragment, and the first binding species and the second binding species selectively bind to different first and second target analytes in the biological sample.

21. The method of claim 1, wherein the first oligonucleotide comprises a nucleotide sequence of RNA bases.

22. The method of claim 1, wherein the first oligonucleotide comprises a nucleotide sequence of DNA bases.

23. The method of claim 1, wherein the first oligonucleotide comprises at least one synthetic nucleotide.

24. 2. The method of claim 1, wherein the first oligonucleotide is completely single-stranded.

25. The method of claim 1 , wherein the first oligonucleotide is partially double-stranded.

26. The method of claim 5 , wherein the dye comprises a chromogenic or fluorescent species.

27. a first substance comprising a first binding species that specifically binds to a first target analyte of a biological sample and a first oligonucleotide conjugated to said first binding species; a second substance comprising a second binding species that specifically binds to a second target analyte of the biological sample and a second oligonucleotide conjugated to the second binding species; a third entity comprising a reactive species and a third oligonucleotide conjugated to the reactive species; a fourth entity comprising a reactive species and a fourth oligonucleotide conjugated to the reactive species; The first labeled species; and Second tagged species wherein each of the first and second labeled species reacts with the reactive species to deposit, in the biological sample, the first and second labeled species or derivatives thereof, respectively.

Citation Information

Patent Citations

  • Detection of Nucleic Acid Differences by Suppression of Accidental DNA Branch Migration

    JP2003507025A

  • Labelling particle comprising fixing fragmented antibody to labelling substance

    JP2009192228A

  • Methods, reagents, and kits for nucleic acid molecule detection

    JP2013511986A

  • Nucleic acid-based linker for detecting and measuring interactions

    JP2014532430A

  • METHODS FOR LOCALIZED IN SITU DETECTION OF mRNA

    JP2016052318A